EUCTR2020-002953-11-DK进行中（未招募）1 期
Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesity - OASIS 1
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 660
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female, age greater than or equal to 18 years at the time of signing informed consent
- •- Body mass index (BMI):
- •greater than or equal to 27.0 kg/m^2 with the presence of at least one of the following weight-related complications (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease OR greater than or equal to 30.0 kg/m^2
- •- History of at least one self-reported unsuccessful dietary effort to lose body weight
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 500
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 160
排除标准
- •- HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening
- •- A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
研究者
相似试验
进行中（未招募）
3 期
Efficacy and safety of oral semaglutide 50 mg once daily in subjects with overweight or obesityObesityJPRN-jRCT2031210297ishida Hiroko60
进行中（未招募）
3 期
Efficacy and safety of oral semaglutide 50 mg once daily in East Asian participants with overweight or obesity (NN9932-4738, OASIS 2)ObesityJPRN-jRCT2011210053Hirose Ryoma158
进行中（未招募）
1 期
Research study to investigate how well semaglutide tablets taken once daily work in people who are overweight or living with obesity (OASIS)EUCTR2020-002953-11-FIovo Nordisk A/S660
进行中（未招募）
1 期
Research study looking at how well semaglutide tablets taken once daily work in people who have a body weight above the healthy range (OASIS 4)MedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesityEUCTR2021-006534-40-PLovo Nordisk A/S300
进行中（未招募）
1 期
Comparing semaglutide once a week to liraglutide once a day as add-on to 1-3 anti-diabetes tablets (OADs) in people with type 2 diabetesDiabetes Mellitus, Type 2EUCTR2016-004965-22-ESovo Nordisk A/S576